At the news
? NEUTRALIMPACT 3/10 PRESS-RELEASE filed Mar 4, 2026 at 08:30 ET
Bicara Therapeutics granted a stock option to purchase 115,000 shares to a new employee as an inducement to employment, issued outside its shareholder-approved equity plans under the newly adopted 2026 Inducement Plan. The move is routine for new hires and does not reflect material financial or clinical developments.
- Bicara Therapeutics issued a stock option to purchase 115,000 shares to a new employee on March 2, 2026.
- Exercise price of $17.59 equals the Nasdaq closing price on the grant date.
- Vesting: 25% on first anniversary, remainder in 12 equal quarterly installments.
- Grant made under the 2026 Inducement Plan, approved by independent directors per Nasdaq Rule 5635(c)(4).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access